HRP20080559T3 - 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds as cck2 modulators - Google Patents
2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds as cck2 modulatorsInfo
- Publication number
- HRP20080559T3 HRP20080559T3 HR20080559T HRP20080559T HRP20080559T3 HR P20080559 T3 HRP20080559 T3 HR P20080559T3 HR 20080559 T HR20080559 T HR 20080559T HR P20080559 T HRP20080559 T HR P20080559T HR P20080559 T3 HRP20080559 T3 HR P20080559T3
- Authority
- HR
- Croatia
- Prior art keywords
- 4alkyl
- phenyl
- alkyl
- group
- carbon
- Prior art date
Links
- GKXZNNBMEDANBL-UHFFFAOYSA-N 2-(quinoxalin-5-ylsulfonylamino)benzamide Chemical class NC(=O)C1=CC=CC=C1NS(=O)(=O)C1=CC=CC2=NC=CN=C12 GKXZNNBMEDANBL-UHFFFAOYSA-N 0.000 title 1
- 229910052799 carbon Inorganic materials 0.000 abstract 8
- 125000005842 heteroatom Chemical group 0.000 abstract 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- -1 10-oxa-4-aza-tricyclo [5.2.1.02,6] dec-4-yl Chemical group 0.000 abstract 3
- 125000005605 benzo group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 150000001721 carbon Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- AQYSYJUIMQTRMV-UHFFFAOYSA-N hypofluorous acid Chemical compound FO AQYSYJUIMQTRMV-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Materials Engineering (AREA)
- Structural Engineering (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49407403P | 2003-08-08 | 2003-08-08 | |
| PCT/US2004/025153 WO2005016896A1 (en) | 2003-08-08 | 2004-08-04 | 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds as cck2 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20080559T3 true HRP20080559T3 (en) | 2009-01-31 |
Family
ID=34193199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20080559T HRP20080559T3 (en) | 2003-08-08 | 2008-11-03 | 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds as cck2 modulators |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US7288651B2 (pt) |
| EP (2) | EP1651621B1 (pt) |
| JP (2) | JP4818110B2 (pt) |
| KR (1) | KR20060060007A (pt) |
| CN (2) | CN1863781A (pt) |
| AR (1) | AR045930A1 (pt) |
| AT (2) | ATE403650T1 (pt) |
| AU (2) | AU2004265312B2 (pt) |
| BR (1) | BRPI0413449A (pt) |
| CA (2) | CA2534887A1 (pt) |
| CR (1) | CR8229A (pt) |
| CY (1) | CY1106486T1 (pt) |
| DE (2) | DE602004004663T2 (pt) |
| DK (2) | DK1651621T3 (pt) |
| EA (1) | EA200600203A1 (pt) |
| EC (1) | ECSP066355A (pt) |
| ES (2) | ES2281834T3 (pt) |
| HR (1) | HRP20080559T3 (pt) |
| IL (1) | IL173591A0 (pt) |
| IS (1) | IS8280A (pt) |
| LT (1) | LT5410B (pt) |
| LV (1) | LV13453B (pt) |
| MX (2) | MXPA06001550A (pt) |
| NO (1) | NO20061122L (pt) |
| NZ (1) | NZ545030A (pt) |
| PL (2) | PL1651621T3 (pt) |
| PT (2) | PT1651622E (pt) |
| SG (1) | SG131114A1 (pt) |
| SI (2) | SI1651621T1 (pt) |
| TW (1) | TW200521120A (pt) |
| UA (1) | UA84025C2 (pt) |
| WO (2) | WO2005016896A1 (pt) |
| ZA (1) | ZA200601946B (pt) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1651621B1 (en) * | 2003-08-08 | 2008-08-06 | Janssen Pharmaceutica N.V. | 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds as cck2 modulators |
| WO2005085188A2 (en) * | 2004-03-02 | 2005-09-15 | Compass Pharmaceuticals Llc | Compounds and methods for anti-tumor therapy |
| WO2005105788A1 (en) * | 2004-04-23 | 2005-11-10 | Takeda San Diego, Inc. | Indole derivatives and use thereof as kinase inhibitors |
| US7947833B2 (en) * | 2004-08-04 | 2011-05-24 | Janssen Pharmaceutica Nv | Preparation of quinoxaline compounds |
| CA2581426A1 (en) * | 2004-09-24 | 2006-04-06 | Janssen Pharmaceutica, N.V. | Sulfonamide compounds |
| FR2904317A1 (fr) | 2006-07-27 | 2008-02-01 | Inst Nat Sante Rech Med | Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques |
| US8592565B2 (en) * | 2007-01-12 | 2013-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Preparation of azide-modified carbon surfaces for coupling to various species |
| US8247403B2 (en) * | 2007-03-07 | 2012-08-21 | Takeda Pharmaceutical Company Limited | Benzoxazepine derivatives and use thereof |
| WO2008124518A1 (en) * | 2007-04-03 | 2008-10-16 | Janssen Pharmaceutica N.V. | Oxo-dihydroisoindole sulfonamide compounds as modulators of the cck2 receptor |
| EP2131245A3 (en) * | 2008-06-02 | 2012-08-01 | ASML Netherlands BV | Lithographic apparatus and its focus determination method |
| US8354557B2 (en) * | 2008-06-17 | 2013-01-15 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated morpholine derivatives |
| US20100305093A1 (en) * | 2009-04-09 | 2010-12-02 | Exelixis, Inc. | Inhibitors of mTOR and Methods of Making and Using |
| EP2486004B1 (en) | 2009-10-09 | 2017-05-03 | Zafgen, Inc. | Sulphone compounds for use in the treatment of obesity |
| EP2590953B1 (en) | 2010-07-09 | 2014-10-29 | Convergence Pharmaceuticals Limited | Tetrazole compounds as calcium channel blockers |
| JP5913310B2 (ja) | 2010-07-22 | 2016-04-27 | ザフゲン，インコーポレイテッド | 三環式化合物ならびにその作製および使用方法 |
| BR112013018771A2 (pt) | 2011-01-26 | 2019-09-17 | Zafgen Inc | compostos de tetrazol e métodos para fazer e usar os mesmos |
| CN103764652B (zh) | 2011-05-06 | 2016-03-23 | 扎夫根股份有限公司 | 三环吡唑磺酰胺化合物及其制备和使用方法 |
| SG194812A1 (en) | 2011-05-06 | 2013-12-30 | Zafgen Inc | Partially saturated tricyclic compounds and methods of making and using same |
| MX343687B (es) | 2011-05-06 | 2016-11-16 | Zafgen Inc | Compuestos sulfonamida tricíclica y métodos para su fabricación y uso. |
| US20120309796A1 (en) | 2011-06-06 | 2012-12-06 | Fariborz Firooznia | Benzocycloheptene acetic acids |
| EP2804866B1 (en) | 2012-01-18 | 2016-11-16 | Zafgen, Inc. | Tricyclic sulfonamide compounds and methods of making and using same |
| BR112014017780A8 (pt) | 2012-01-18 | 2017-07-11 | Zafgen Inc | Compostos de sulfona tricíclicos e métodos para fazer e usar os mesmos |
| DK3345899T3 (da) * | 2012-03-01 | 2020-05-11 | Allergan Inc | Benzofuran-2-sulfonamidderivater som kemokinreceptormodulatorer |
| MX2015005733A (es) | 2012-11-05 | 2016-02-10 | Zafgen Inc | Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad. |
| WO2014071363A1 (en) | 2012-11-05 | 2014-05-08 | Zafgen, Inc. | Tricyclic compounds and methods of making and using same |
| NZ707773A (en) | 2012-11-05 | 2019-05-31 | Zafgen Inc | Methods of treating liver diseases |
| JP6361168B2 (ja) * | 2013-06-17 | 2018-07-25 | Jsr株式会社 | 液晶配向剤、液晶配向膜、液晶表示素子、液晶表示素子の製造方法、重合体及び化合物 |
| CN103524386B (zh) * | 2013-10-24 | 2016-05-18 | 江苏鼎龙科技有限公司 | 2-氨基-4-甲磺酰胺甲基苯甲酸甲酯的制备方法 |
| CA2929858C (en) | 2013-11-22 | 2022-03-29 | CL BioSciences LLC | Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis |
| KR20170016754A (ko) * | 2015-08-04 | 2017-02-14 | 씨제이헬스케어 주식회사 | 크로마논 유도체의 신규한 제조방법 |
| CN106565509A (zh) * | 2016-11-03 | 2017-04-19 | 江苏鼎龙科技有限公司 | 2‑氨基‑4‑甲氨基苯甲酸甲酯盐酸盐的制备方法 |
| KR101894091B1 (ko) * | 2018-01-23 | 2018-08-31 | 씨제이헬스케어 주식회사 | 크로마논 유도체의 신규한 제조방법 |
| CN108218806B (zh) * | 2018-04-02 | 2019-03-01 | 上海馨远医药科技有限公司 | 一种n-叔丁氧羰基吗啉-3-羧酸的制备方法 |
| CN111285806B (zh) * | 2018-12-06 | 2022-04-15 | 中国医学科学院药物研究所 | 吡唑类化合物及其制备方法、用途和药物组合物 |
| CN116675684B (zh) * | 2023-08-02 | 2023-11-07 | 上海翰森生物医药科技有限公司 | 含炔基稠环类衍生物拮抗剂、其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9200420D0 (en) * | 1992-01-09 | 1992-02-26 | James Black Foundation The Lim | Amino acid derivatives |
| DE69426205T2 (de) * | 1993-08-10 | 2001-03-08 | Black James Foundation | Gastrin-und cck-rezeptorligande |
| US6239131B1 (en) | 1996-12-10 | 2001-05-29 | Zeria Pharmaceutical Co., Ltd. | 1,5 Benzodiazepine derivatives |
| DE10121003A1 (de) | 2001-04-28 | 2002-12-19 | Aventis Pharma Gmbh | Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
| DE10121002A1 (de) | 2001-04-28 | 2002-11-14 | Aventis Pharma Gmbh | Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen |
| DE10128331A1 (de) | 2001-06-12 | 2002-12-19 | Aventis Pharma Gmbh | Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen |
| DE10134721A1 (de) * | 2001-07-17 | 2003-02-06 | Bayer Ag | Tetrahydrochinoxaline |
| ITTO20020674A1 (it) | 2002-07-26 | 2004-01-26 | Rotta Research Lab | Derivati antranilici ad attivita' anticolecistochininica (anti-cck-1), procedimento per la loro preparazione e loro uso farmaceutico |
| US6943170B2 (en) * | 2002-11-14 | 2005-09-13 | Bristol-Myers Squibb Company | N-cycloalkylglycines as HIV protease inhibitors |
| EP1651621B1 (en) * | 2003-08-08 | 2008-08-06 | Janssen Pharmaceutica N.V. | 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds as cck2 modulators |
| CA2581426A1 (en) * | 2004-09-24 | 2006-04-06 | Janssen Pharmaceutica, N.V. | Sulfonamide compounds |
-
2004
- 2004-08-04 EP EP04780055A patent/EP1651621B1/en active Active
- 2004-08-04 KR KR1020067002650A patent/KR20060060007A/ko not_active Application Discontinuation
- 2004-08-04 DE DE602004004663T patent/DE602004004663T2/de active Active
- 2004-08-04 CN CNA2004800290901A patent/CN1863781A/zh active Pending
- 2004-08-04 ES ES04780056T patent/ES2281834T3/es active Active
- 2004-08-04 AU AU2004265312A patent/AU2004265312B2/en not_active Expired - Fee Related
- 2004-08-04 BR BRPI0413449-4A patent/BRPI0413449A/pt not_active IP Right Cessation
- 2004-08-04 JP JP2006523230A patent/JP4818110B2/ja active Active
- 2004-08-04 ES ES04780055T patent/ES2310294T3/es active Active
- 2004-08-04 SG SG200701706-4A patent/SG131114A1/en unknown
- 2004-08-04 EP EP04780056A patent/EP1651622B1/en active Active
- 2004-08-04 US US10/910,983 patent/US7288651B2/en active Active
- 2004-08-04 UA UAA200601931A patent/UA84025C2/ru unknown
- 2004-08-04 SI SI200430901T patent/SI1651621T1/sl unknown
- 2004-08-04 MX MXPA06001550A patent/MXPA06001550A/es active IP Right Grant
- 2004-08-04 MX MXPA06001482A patent/MXPA06001482A/es active IP Right Grant
- 2004-08-04 US US10/910,925 patent/US7304051B2/en active Active
- 2004-08-04 AT AT04780055T patent/ATE403650T1/de not_active IP Right Cessation
- 2004-08-04 PT PT04780056T patent/PT1651622E/pt unknown
- 2004-08-04 CN CNA200480029094XA patent/CN1863782A/zh active Pending
- 2004-08-04 SI SI200430245T patent/SI1651622T1/sl unknown
- 2004-08-04 AU AU2004265311A patent/AU2004265311A1/en not_active Abandoned
- 2004-08-04 PL PL04780055T patent/PL1651621T3/pl unknown
- 2004-08-04 NZ NZ545030A patent/NZ545030A/en unknown
- 2004-08-04 AT AT04780056T patent/ATE353322T1/de not_active IP Right Cessation
- 2004-08-04 CA CA002534887A patent/CA2534887A1/en not_active Abandoned
- 2004-08-04 DE DE602004015614T patent/DE602004015614D1/de active Active
- 2004-08-04 CA CA2534885A patent/CA2534885C/en active Active
- 2004-08-04 PL PL04780056T patent/PL1651622T3/pl unknown
- 2004-08-04 WO PCT/US2004/025153 patent/WO2005016896A1/en active IP Right Grant
- 2004-08-04 JP JP2006523231A patent/JP2007501842A/ja not_active Withdrawn
- 2004-08-04 WO PCT/US2004/025154 patent/WO2005016897A1/en active IP Right Grant
- 2004-08-04 DK DK04780055T patent/DK1651621T3/da active
- 2004-08-04 EA EA200600203A patent/EA200600203A1/ru unknown
- 2004-08-04 DK DK04780056T patent/DK1651622T3/da active
- 2004-08-04 PT PT04780055T patent/PT1651621E/pt unknown
- 2004-08-06 AR ARP040102814A patent/AR045930A1/es not_active Application Discontinuation
- 2004-08-06 TW TW093123552A patent/TW200521120A/zh unknown
-
2006
- 2006-01-31 IS IS8280A patent/IS8280A/is unknown
- 2006-02-07 IL IL173591A patent/IL173591A0/en unknown
- 2006-02-08 EC EC2006006355A patent/ECSP066355A/es unknown
- 2006-02-08 CR CR8229A patent/CR8229A/es unknown
- 2006-02-08 LV LVP-06-18A patent/LV13453B/en unknown
- 2006-03-07 ZA ZA200601946A patent/ZA200601946B/en unknown
- 2006-03-07 LT LT2006017A patent/LT5410B/lt not_active IP Right Cessation
- 2006-03-08 NO NO20061122A patent/NO20061122L/no not_active Application Discontinuation
-
2007
- 2007-04-04 CY CY20071100473T patent/CY1106486T1/el unknown
- 2007-12-04 US US11/950,326 patent/US7563895B2/en active Active
-
2008
- 2008-11-03 HR HR20080559T patent/HRP20080559T3/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20080559T3 (en) | 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds as cck2 modulators | |
| CY1111481T1 (el) | Υποκατεστημενα αρυλοκυκλοπροπυλακεταμιδια ως ενεργοποιητες γλυκοκινασης | |
| MEP61208A (en) | Novel compounds having inhibitory activity against sodium-dependant transporter | |
| CY1111671T1 (el) | Ετεροκυκλικη ενωση | |
| ME00443B (me) | Kristalni oblik tercijalne butilaminske soli perindoprila | |
| AR057914A1 (es) | Compuestos organicos de azufre y su uso | |
| CR8827A (es) | Compuesto heterociclico fusionado | |
| RS52313B (en) | MYTHOSIS PROGRESS INHIBITION UNITS | |
| RS52307B (en) | CONDENSED CYCLIC UNITS | |
| ME01992B (me) | Jedinjenje diarilhidantoina | |
| TW200833251A (en) | Pesticidal compositions | |
| AR044695A1 (es) | Derivados de azolidina, utiles como herbicidas. | |
| AR069802A1 (es) | Compuestos de carbamoilo como inhibidores de dgat1 190 | |
| EA200800873A1 (ru) | Конденсированные гетероциклические соединения, полезные в качестве модуляторов киназы | |
| ATE387452T1 (de) | Spiroverbindungen mit npy antagonistischer wirkung | |
| CY1113657T1 (el) | Νεα παραγωγα βενζοφαινονης ή αλατα αυτων | |
| RS54175B1 (en) | BROMODOMEN INHIBITORS AND THEIR APPLICATION | |
| RS52872B (en) | PIRAL UNITS | |
| EA201070782A1 (ru) | Производные оксадиазола, активные в отношении сфингозин-1-фосфата(sip) | |
| RS52661B (en) | THERAPEUTIC MEANS | |
| EA200200819A1 (ru) | Кристаллическая форма ii линезолида | |
| RS52900B (en) | Benzoylpyrazole Compound, Process for Production and Production of Herbicides Containing Them | |
| AR054386A1 (es) | Moduladores de quinasas con estructuras de alquiloquinolina y alquilquinazolina | |
| RS51644B (en) | UNITS AND PREPARATIONS AS CHANNEL INHIBITORS ACTIVATING PROSTHESES | |
| HRP20070286T3 (en) | Substituted diketopiperazines and their use as oxytocyn antagonists |